1. RenaGel®, a nonabsorbed calcium- and aluminum-free phosphate binder, lowers serum phosphorus and parathyroid hormone 
Eduardo A. Slatopolsky, Steven K. Burke, Maureen A. Dillon 
Kidney International 
Volume 55, Issue 1, Pages (January 1999)
DOI: /j x
Copyright © 1999 International Society of Nephrology Terms and Conditions

2. Figure 1
Structure of RenaGel®, cross-linked poly(allylamine hydrochloride).
Kidney International  , DOI: ( /j x)
Copyright © 1999 International Society of Nephrology Terms and Conditions

3. Figure 2
Effect of RenaGel® on serum phosphorus. During the treatment period with RenaGel the decrease in serum phosphorus 9.1 ± 2.4 to 6.6 ± 1.9 mg/dl was statistically significant (P ).
Kidney International  , DOI: ( /j x)
Copyright © 1999 International Society of Nephrology Terms and Conditions

4. Figure 3 Effect of RenaGel® on serum calcium.
Kidney International  , DOI: ( /j x)
Copyright © 1999 International Society of Nephrology Terms and Conditions

5. Figure 4 Effect of RenaGel® on Ca × P product.
Kidney International  , DOI: ( /j x)
Copyright © 1999 International Society of Nephrology Terms and Conditions

6. Figure 5
Effect of RenaGel® on serum parathyroid hormone (PTH). At the end of the 2 week treatment, the decrease in PTH was statistically significant (P < ). After RenaGel was discontinued there was a significant increase in the levels of serum PTH (P < ).
Kidney International  , DOI: ( /j x)
Copyright © 1999 International Society of Nephrology Terms and Conditions

7. Figure 6 Effect of RenaGel® on serum total cholesterol.
Kidney International  , DOI: ( /j x)
Copyright © 1999 International Society of Nephrology Terms and Conditions

8. Figure 7
Effect of RenaGel® on serum low density lipoprotein (LDL). The decrease in LDL was highly statistically significant (P < ).
Kidney International  , DOI: ( /j x)
Copyright © 1999 International Society of Nephrology Terms and Conditions